Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | $10.00M |
| Net Income (Most Recent Fiscal Year) | $-377.74M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.17 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -48416.40% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -122.45% |
| Return on Assets (Trailing 12 Months) | -58.04% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.93 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.93 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.57 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.79 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.77 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-8.99 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 65.18M |
| Free Float | 50.84M |
| Market Capitalization | $2.08B |
| Average Volume (Last 20 Days) | 0.72M |
| Beta (Past 60 Months) | -1.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.00% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |